TY - JOUR
TI - Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome
AU - Billa, E.
AU - Kapolla, N.
AU - Nicopoulou, S.C.
AU - Koukkou, E.
AU - Venaki, E.
AU - Milingos, S.
AU - Antsaklis, A.
AU - Adamopoulos, D.A.
JO - Gynecological Endocrinology
PY - 2009
VL - 25
TODO - 7
SP - 427-434
PB - 
SN - 0951-3590, 1473-0766
TODO - 10.1080/09513590902770172
TODO - follitropin;  glucose;  gonadorelin;  insulin;  luteinizing hormone;  metformin;  placebo;  prolactin;  protirelin;  thyrotropin, adult;  anovulation;  area under the curve;  article;  clinical article;  clinical trial;  controlled clinical trial;  controlled study;  dynamics;  female;  follitropin blood level;  follitropin release;  gonadorelin test;  human;  hypophysis function;  insulin blood level;  insulin release;  insulin response;  luteinizing hormone blood level;  luteinizing hormone release;  menstrual cycle;  oral glucose tolerance test;  outcome assessment;  ovary polycystic disease;  patient compliance;  priority journal;  prolactin blood level;  prolactin release;  prospective study;  protirelin test;  randomized controlled trial;  thyrotropin blood level;  thyrotropin release, Adolescent;  Adult;  Androgens;  Anovulation;  Female;  Glucose Tolerance Test;  Hormones;  Humans;  Hypoglycemic Agents;  Insulin;  Insulin Resistance;  Luteinizing Hormone;  Metformin;  Ovulation;  Pituitary Gland;  Placebos;  Polycystic Ovary Syndrome;  Prolactin;  Prospective Studies;  Young Adult
TODO - Aim. To elucidate the dynamics of FSH, LH, prolactin PRL, TSH and insulin secretion in women with polycystic ovarian syndrome PCOS treated with metformin MET. Patients and methods. In a prospective, controlled and randomised trial, 32 women with PCOS and 32 with normal cycle were recruited to receive MET 850 mg b.i.d. or placebo n: 16 for each subgroup for an average of 40 days. Pituitary function and insulin secretion were assessed before and after intervention by GnRH-TRH tests and oral glucose tolerance test induced insulin response. Results. Basal and area under the response curve AURC LH values were higher in PCOS than in normal controls before MET and declined following treatment in the former group P < 0.05. Ovulatory PCOS responders had lower basal LH, AURCLH and AURCPRL values during MET than anovulatory cases P < 0.05 for all and AURCins was lower in ovulatory than anovulatory PCOS before and on MET P < 0.02P < 0.05, with a rise of QUICKY index in the former group during MET treatment P < 0.05. FSH and TSH were similar. Conclusions. MET administration lowered LH activity in all PCOS women and in ovulatory responders and also compromised PRL stimulated secretion in the latter cases. These findings were indicative of an effect of MET on pituitary activity. © 2009 Informa UK Ltd All rights reserved.
ER -